New use for old drugs: Epirubicin in colorectal cancer

New Approaches to Use Nanoparticles for Treatment of Colorectal Cancer; a Brief Review

Nanoparticles have been at the center of research focus as a new promising material for the treatment of cancer in recent years. Although many chemotherapy drugs for cancer treatment are available, their potential toxicity is the main point of concern. On the other hand, the conventional chemotherapeutic approach has not been found to be very efficient in colorectal cancer (CRC) as the drug mol...

A review on miRNAs as new biomarkers for colorectal cancer

Background & Objective: Since colorectal cancer does not often have phenotypic symptoms in the early stages, the study of biomarkers for the diagnosis and prognosis of the tumor is very important. MicroRNAs are one of the most important biomarkers which attract the attention of many researchers due to a variety of reasons, including their non-invasive nature; these molecules are a group of non-...

Reanalysis of cancer drugs: old drugs, new tricks.

George F. Vande Woude, Gary J. Kelloff, Raymond W. Ruddon, Han-Mo Koo, Caroline C. Sigman, J. Carl Barrett, Robert W. Day, Adam P. Dicker, Robert S. Kerbel, David R. Parkinson, and William J. Slichenmyer Van Andel Research Institute, Grand Rapids, Michigan; Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; Johnson & Johnson...

Special Review Reanalysis of Cancer Drugs: Old Drugs, New Tricks

George F. Vande Woude, Gary J. Kelloff, Raymond W. Ruddon, Han-Mo Koo, Caroline C. Sigman, J. Carl Barrett, Robert W. Day, Adam P. Dicker, Robert S. Kerbel, David R. Parkinson, and William J. Slichenmyer Van Andel Research Institute, Grand Rapids, Michigan; Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; Johnson & Johnson...

Drugs old and new.